![](https://news.europawire.eu/wp-content/uploads/2020/06/astrazeneca-sciencefromatoz-144x144.jpg)
ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release